Currently Viewing:
Newsroom
Currently Reading
Biomarker Use in Colorectal Cancer
December 17, 2019 – Maggie L. Shaw
At Increasing Levels of Sensitivity, NGS-MRD Detects CLL in Bone Marrow
December 14, 2019 – AJMC Staff
5 Things About Cancer, Genetics, and Germline Screening
December 06, 2019 – Allison Inserro
NCCN Releases Updated Breast, Pancreatic, Ovarian Genetic Screening Guidelines
December 05, 2019 – Allison Inserro
Researchers Use Tumor Slices to Understand Microenvironment, Test Therapeutics
November 28, 2019 – AJMC Staff
Pancreatic Tumor Classification Could Guide Treatment, Researchers Say
November 22, 2019 – AJMC Staff
RNA Sequencing May Be Able to Help Target Therapies for Pediatric Cancers
November 16, 2019 – Laura Joszt
Researchers Identify mRNA Biomarker to Predict Response to Chemotherapy
November 09, 2019 – AJMC Staff
Microsoft Partnering With Cancer Researchers on Genomic Database
November 02, 2019 – Allison Inserro

Biomarker Use in Colorectal Cancer

Maggie L. Shaw
Despite a 20% drop in mortality since 2009, colorectal cancer accounted for 9.8% (881,000) of deaths worldwide in 2018 and represents 10.2% of all cancer cases worldwide. It is No. 3 on the list of most prevalent cancers worldwide—1.8 million new cases in 2018—behind only lung cancer and breast cancer.
Despite a 20% drop in mortality since 2009, colorectal cancer (CRC) accounted for 9.8% (881,000) of deaths worldwide in 2018 and represents 10.2% of all cancer cases worldwide. It is No. 3 on the list of most prevalent cancers worldwide—1.8 million new cases in 2018—behind only lung cancer and breast cancer.

CRC tumors are heterogeneous in both their inter- and intratumor characteristics due to chromosomal instability (CIN), microsatellite instability (MSI), aberrant DNA methylation, and DNA repair defects. These same things, however, dictate how patients respond to therapy. Therefore, using biomarkers for early detection, diagnosis, and staging make up the ideal clinical strategy that leads to disease recovery.

A group of researchers from the University of Naples Federico II, in a recent issue of the journal, Cancers, reviewed molecular biomarkers from tumor tissue and liquid biopsy currently being used in CRC, that help to decide on the appropriate therapy for patients. We discuss several of these below.

In confirmed cases of hereditary nonpolyposis CRC (also known as Lynch syndrome), mutations in the MMR gene are used to make treatment decisions. Tumors that are MSI high typically mean better outcomes and higher rates of survival compared with tumors that are MSI low or stable; however, this particular mutation also doesn’t respond as well to 5-Flurouracil (5-FU)-based chemotherapy compared with the same.

With familial adenomatous polyposis, tumors that feature the CIN phenotype and APC gene mutations are markers of a poor prognosis, but they do help to identify high-risk patients with stage II disease who could benefit from adjuvant chemotherapy.

Variants in the GREM1 and BRAF genes, meanwhile, predispose individuals to hereditary mixed polyposis, with tumors that feature BRAF and KRAS mutations along with MSI. KRAS mutations are markers of a poor prognosis, but they also help indicate patients who might not respond to anti-EGFR therapy.

Lastly, the 4 consensus molecular subtypes (CMS) of CRC identified by the CRC Subtyping Consortium—CMS1, CMS2, CMS3, and CMS4—are used to identify patients with poor progression-free survival (PFS) (CMS1 and CMS2), better PFS and overall survival (CMS4), and good response to 5-FU treatment (CMS1, CMS2, and CMS3).

“All of these mechanisms confer specific features to each tumor in terms of malignancy, aggressiveness, invasion, and response to therapy,” the study authors stated. “Consequently, the identification and standardization of cancer prognostic and predictive molecular biomarkers is becoming increasingly more relevant.”

Reference

Turano M, Delrio P, Rega D, et al. Promising colorectal cancer biomarkers for precision prevention and oncology. Cancers. 2019;11(12):1932-1951. 

Related Articles

The Fast Pace of CAR T-Cell Innovation Caused an Array of Challenges in Treatment
RNA Sequencing May Be Able to Help Target Therapies for Pediatric Cancers
Pancreatic Tumor Classification Could Guide Treatment, Researchers Say
The Value of Genomic Profiling for Women With Breast Cancer
At Increasing Levels of Sensitivity, NGS-MRD Detects CLL in Bone Marrow
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up